Memorial Hospital Research Laboratories

The Charles Rudin Lab

Research

Charles M. Rudin, MD, PhD

Professor

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Featured News

In the Clinic

Unexpected Finding Reveals New Target for Aggressive Form of Lung Cancer

Tuesday, December 1, 2020

MSK Leaders Recognized in the 40 Under 40 in Cancer Class of 2020

Thursday, October 15, 2020

ASCO 2020: Advances in the Treatment of Small-Cell Lung Cancer

Thursday, May 28, 2020

View All Featured News

Publications

Chow, A., Schad, S., Green, M., Hellmann, M.D., Allaj, V., et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell (2021).

Hulton, C. H., Costa, E. A., Shah, N. S., Quintanal-Villalonga, A., Heller, G., de Stanchina, E., Rudin, C. M. & Poirier, J. T. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nat Cancer 1, 359-369 (2020).

Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, A., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., Hayatt, O., Buonocore, D. J., Rekhtman, N., Shen, R., Arbour, K. C., Donoghue, M., Poirier, J. T., Sen, T. & Rudin, C. M. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep 33, 108444 (2020).

Quintanal-Villalonga, A., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T. & Rudin, C. M. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol 17, 360-371 (2020).

Taniguchi, H., Sen, T. & Rudin, C. M. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Front Oncol 10, 741 (2020).

View All Publications

People

Charles M. Rudin, MD, PhD

Professor

Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
MD, PhD, University of Chicago Pritzker School of Medicine

rudinc@mskcc.org: Email Address
View physician profile: Physician profile

Members

Triparna Sen, PhD — Triparna Sen
Assistant Attending/Lab Co-Director

John Poirier — John T. Poirier
Assistant Professor, Director, Preclinical Therapeutics Program, Perlmutter Cancer Center, NYU Langone Health

Nisarg Shah
Senior Research Assistant/Lab Manager

Andrew Chow
Assistant Attending, Thoracic Oncology Service

W. Victoria Lai — Victoria Lai
Assistant Attending, Thoracic Oncology Service

Álvaro Quintanal Villalonga
Research Fellow

Lab Alumni

Eric Gardner
Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS — Christopher Hulton
Research Scientist at C4 Therapeutic, Watertown, Massachusetts

James Laird
Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok — Benjamin Lok
Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Linde Miles
Postdoctoral Research Fellow, Ross Levine Lab, MSKCC

Lab Affiliations

Open Positions

Career Opportunities

Apply now

Get in Touch

rudinc@mskcc.org

Lab Head Email

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

AbbVie
Provision of Services
Amgen
Provision of Services (uncompensated)
Ascentage Pharma
Provision of Services
Astra Zeneca
Provision of Services
Bridge Medicines
Provision of Services (uncompensated)
Celgene
Provision of Services
Chugai Pharmaceuticals
Provision of Services
Daiichi Sankyo
Provision of Services

Elucida Oncology
Provision of Services (uncompensated)
Genentech
Provision of Services
Harpoon Therapeutics, Inc.
Provision of Services
Loxo Oncology
Provision of Services
MORE Health, Inc
Provision of Services
Roche
Provision of Services
SynDevRx Inc
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures